You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FT538, AML, Daratumumab, CD38

Showing 1 - 25 of 1,940
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia Trial in Minneapolis (Daratumumab/rHuPH20, FT538, Fludarabine)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 3, 2021

Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma Trial in United States (FT538, Cyclophosphamide, Fludarabine)

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Denver, Colorado
  • +8 more
May 19, 2022

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia Trial (Darzalex)

Not yet recruiting
  • Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
  • (no location specified)
Feb 27, 2023

HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency Trial in Minneapolis (FT538, Vorinostat)

Not yet recruiting
  • HIV-1-infection
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 31, 2023

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid

Completed
  • Minimal Residual Disease
  • +3 more
  • Daratumumab
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 2, 2022

Multiple Myeloma Trial in Worldwide (GEN3014 (HexaBody®-CD38))

Recruiting
  • Multiple Myeloma
  • +2 more
  • Atlanta, Georgia
  • +19 more
Dec 12, 2022

Hemophilia A With Inhibitor Trial (SCT800 and Daratumumab)

Not yet recruiting
  • Hemophilia A With Inhibitor
  • SCT800 and Daratumumab
  • (no location specified)
May 24, 2023

High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

Not yet recruiting
  • High-Risk de Novo Multiple Myeloma
  • Badalona, Spain
  • +9 more
Apr 27, 2023

Multiple Myeloma Trial in Rochester (procedure, biological, drug)

Not yet recruiting
  • Multiple Myeloma
  • Biospecimen Collection
  • +12 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Sep 15, 2023

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder Trial in Tianjin (Daratumumab, Placebo)

Recruiting
  • Neuromyelitis Optica
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University General Hospital
Oct 19, 2022

Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Recruiting
  • Acute Myeloid Leukemia
  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)

Recruiting
  • Multiple Myeloma
  • 89Zr-daratumumab PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Aug 1, 2022

Multiple Myeloma Trial in Amsterdam (all-trans retinoic acid (ATRA))

Active, not recruiting
  • Multiple Myeloma
  • all-trans retinoic acid (ATRA)
  • Amsterdam, NH, Netherlands
    VU University Medical Center
May 5, 2022

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Stem Cells Mobilization, colLection and Engraftment in Newly

Recruiting
  • Multiple Myeloma
  • +3 more
  • Rome, Italy
    Fondazione Policlinico Universitario A.Gemelli IRCCS
Apr 28, 2023

Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
Jan 17, 2023

AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease Trial in San Francisco (Venetoclax, Dexamethasone,

Not yet recruiting
  • AL Amyloidosis
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 16, 2022

AL Amyloidosis Trial (procedure, drug, other)

Not yet recruiting
  • AL Amyloidosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +15 more
  • (no location specified)
Aug 28, 2023

Glioblastoma Trial in Morgantown (Daratumumab)

Recruiting
  • Glioblastoma
  • Morgantown, West Virginia
    West Virginia University Cancer Institute Mary Babb Randolph Can
Dec 5, 2022

Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Woolloongabba, Queensland, Australia
  • +117 more
Aug 3, 2022

Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial in United States (TAK-981, Mezagitamab, Daratumumab and

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma (RRMM)
  • Scottsdale, Arizona
  • +11 more
Jan 6, 2022

Multiple Myeloma Trial in Baltimore (Ciforadenant, daratumumab)

Completed
  • Multiple Myeloma
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 9, 2022